Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT

European Journal of Heart Failure

Volumn 16, Issue 7, 2014, Pages 810-816

  Komajda, Michel ^a   Böhm, Michael ^b   Borer, Jeffrey S ^c   Ford, Ian ^d   Robertson, Michele ^d   Manolis, Athanasios J ^e   Tavazzi, Luigi ^f   Swedberg, Karl ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b SAARLAND UNIVERSITY   (Germany)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e Asklepeion Hospital   (Greece)

^f MARIA CECILIA HOSPITAL   (Italy)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Blood pressure; Ivabradine; Outcomes; SHIFT; Systolic heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; HEART FAILURE, SYSTOLIC; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; SYSTOLE; TREATMENT OUTCOME;

AGED; BENZAZEPINES; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; HYPERTENSION; HYPOTENSION; MALE; MIDDLE AGED; PROGNOSIS; SYSTOLE; TREATMENT OUTCOME;

EID: 84903757137     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.114     Document Type: Article

References (24)

1. Gheorghiade M, Vaduganathan M, Ambrosy A, Bohm M, Campia U, Cleland JG, Fedele F, Fonarow GC, Maggioni AP, Mebazaa A, Mehra M, Metra M, Nodari S, Pang PS, Ponikowski P, Sabbah HN, Komajda M, Butler J,. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev 2013; 18: 107-122.
2. Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subacius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M,. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J 2013; 165: 216-225.
3. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A,. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011; 107: 1208-1214.
4. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ,. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol 2008; 52: 2000-2007.
5. Cheng RK, Horwich TB, Fonarow GC,. Relation of systolic blood pressure to survival in both ischemic and nonischemic systolic heart failure. Am J Cardiol 2008; 102: 1698-1705.
6. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, Mayet J, Francis DP,. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart 2009; 95: 56-62.
7. Mak G, Murphy NF, Ali A, Walsh A, O'Loughlin C, Conlon C, McCaffrey D, Ledwidge M, McDonald K,. Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail 2008; 14: 555-560.
8. Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Topper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R,. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011; 13: 670-680.
9. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC,. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226. (Pubitemid 44708052)
10. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875-885.
11. Swedberg K, Komajda M, B'hm M, Borer JS, Ford I, Tavazzi L,. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010; 12: 75-81.
12. Dickstein K, Cohen-Solal A, Filippatos G, Mac Murray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K,. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989.
13. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ,. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
14. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA,. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005; 26: 2259-2268. (Pubitemid 41541389)
15. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shiba N, Shimokawa H,. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure. Circ J 2013; 77: 2954-2962.
16. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L,. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-1084.
17. Metra M, Nodari S, Dei CL,. Beta-blockade in heart failure: selective versus nonselective agents. Am J Cardiovasc Drugs 2001; 1: 3-14.
18. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L,. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
19. DiFrancesco D,. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006; 53: 399-406.
20. Savelieva I, Camm AJ,. I(f) inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008; 31: 95-107. (Pubitemid 351175614)
21. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C,. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2006; 61: 127-137. (Pubitemid 43382606)
22. f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J 2009; 30: 540-548.
23. Miller WL, Skouri HN,. Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?). J Card Fail 2009; 15: 101-107.
24. White M, Desai RV, Guichard JL, Mujib M, Aban IB, Ahmed MI, Feller MA, de DS, Ahmed A. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST. Can J Cardiol 2012; 28: 354-359.